723 related articles for article (PubMed ID: 27840965)
1. Breast cancer stem cells expressing different stem cell markers exhibit distinct biological characteristics.
Shao J; Fan W; Ma B; Wu Y
Mol Med Rep; 2016 Dec; 14(6):4991-4998. PubMed ID: 27840965
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
[TBL] [Abstract][Full Text] [Related]
3. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis.
Li W; Ma H; Zhang J; Zhu L; Wang C; Yang Y
Sci Rep; 2017 Oct; 7(1):13856. PubMed ID: 29062075
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer stem cells and intrinsic subtypes: controversies rage on.
Nakshatri H; Srour EF; Badve S
Curr Stem Cell Res Ther; 2009 Jan; 4(1):50-60. PubMed ID: 19149630
[TBL] [Abstract][Full Text] [Related]
5. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.
de Beça FF; Caetano P; Gerhard R; Alvarenga CA; Gomes M; Paredes J; Schmitt F
J Clin Pathol; 2013 Mar; 66(3):187-91. PubMed ID: 23112116
[TBL] [Abstract][Full Text] [Related]
6. Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer.
Duhachek-Muggy S; Qi Y; Wise R; Alyahya L; Li H; Hodge J; Zolkiewska A
Mol Cancer; 2017 Feb; 16(1):32. PubMed ID: 28148288
[TBL] [Abstract][Full Text] [Related]
7. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
[TBL] [Abstract][Full Text] [Related]
8. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
[TBL] [Abstract][Full Text] [Related]
9. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
Kapucuoğlu N; Bozkurt KK; Başpınar Ş; Koçer M; Eroğlu HE; Akdeniz R; Akçil M
Pathol Res Pract; 2015 Oct; 211(10):740-7. PubMed ID: 26298632
[TBL] [Abstract][Full Text] [Related]
10. A novel molecular marker of breast cancer stem cells identified by cell-SELEX method.
Lu M; Zhou L; Zheng X; Quan Y; Wang X; Zhou X; Ren J
Cancer Biomark; 2015; 15(2):163-70. PubMed ID: 25519016
[TBL] [Abstract][Full Text] [Related]
11. ALDH(+)/CD44(+)/CD24(-) expression in cells from body cavity fluids.
Krishan A; Sharma D; Sharma S; Hamelik RM; Ganjei-Azar P; Nadji M
Cytometry B Clin Cytom; 2010 May; 78(3):176-82. PubMed ID: 20043317
[TBL] [Abstract][Full Text] [Related]
12. Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
Bane A; Viloria-Petit A; Pinnaduwage D; Mulligan AM; O'Malley FP; Andrulis IL
Breast Cancer Res Treat; 2013 Jul; 140(1):195-205. PubMed ID: 23813303
[TBL] [Abstract][Full Text] [Related]
13. Distinct breast cancer stem/progenitor cell populations require either HIF1α or loss of PHD3 to expand under hypoxic conditions.
Iriondo O; Rábano M; Domenici G; Carlevaris O; López-Ruiz JA; Zabalza I; Berra E; Vivanco Md
Oncotarget; 2015 Oct; 6(31):31721-39. PubMed ID: 26372732
[TBL] [Abstract][Full Text] [Related]
14. Characteristic genes in luminal subtype breast tumors with CD44+CD24-/low gene expression signature.
Tsunoda Y; Sakamoto M; Sawada T; Sasaki A; Yamamoto G; Tachikawa T
Oncology; 2011; 81(5-6):336-44. PubMed ID: 22237177
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.
Hashimoto K; Shimizu C; Tsuda H; Saji S; Osaki A; Shigekawa T; Aogi K
Oncology; 2012; 82(3):168-74. PubMed ID: 22433454
[TBL] [Abstract][Full Text] [Related]
16. Are CD44
Ryspayeva DE; Smolanka II; Dudnichenko АS; Lyashenko AA; Grinevich YA; Gurianov VG; Koshubarova MV; Seleznev AA
Exp Oncol; 2017 Sep; 39(3):224-228. PubMed ID: 28967636
[TBL] [Abstract][Full Text] [Related]
17. Co-expression of stem cell markers ALDH1 and CD44 in non-malignant and neoplastic lesions of the breast.
DA Cruz Paula A; Marques O; Rosa AM; DE Fátima Faria M; Rêma A; Lopes C
Anticancer Res; 2014 Mar; 34(3):1427-34. PubMed ID: 24596390
[TBL] [Abstract][Full Text] [Related]
18. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
[TBL] [Abstract][Full Text] [Related]
19. CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549.
Roudi R; Madjd Z; Ebrahimi M; Samani FS; Samadikuchaksaraei A
Cell Mol Biol Lett; 2014 Mar; 19(1):23-36. PubMed ID: 24363164
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic and microRNA characterization of the neglected CD24+ cell population in MCF-7 breast cancer 3-dimensional spheroid culture.
Boo L; Yeap SK; Ali NM; Ho WY; Ky H; Satharasinghe DA; Liew WC; Tan SW; Wang ML; Cheong SK; Ong HK
J Chin Med Assoc; 2020 Jan; 83(1):67-76. PubMed ID: 31904742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
